News

 April 2019

HHPF past president David Rabago, MD, presented the abstracts of two prolotherapy studies as lectures at the elite North American Primary Care Research Group (NAPCRG) conference in Chicago, IL, in November 2018. Both won prestigious PEARL awards (https://www.napcrg.org/pearls); each was selected from among over 1000 peer-reviewed abstracts as those “most likely to influence clinical practice”.

The awards suggest that prolotherapy is gaining visibility in conventional (compared with alternative) medical venues. The HHPF is involved in both studies through funding (tennis elbow study) and collaboration (both studies). Principal investigators Michael Yelland (Australia) and Regina Sit (Hong Kong) have presented at the annual HHPF Prolotherapy Research Symposium; the manuscripts for both studies are in review with peer-reviewed journals.

Abstracts Presented:

Intra-Articular Hypertonic Dextrose Prolotherapy Reduces Knee Pain in Knee Osteoarthritis: A One Year Blinded Randomized Controlled Trial
David Rabago, MD; Ricky Wu; Kenneth Reeves, MD; Dicken Chan; Benjamin HK Yip; Vincent Chung; Samuel, Yeungshan Wong; Regina Sit

Prolotherapy, Physiotherapy and Combination Care for Lateral Epicondylalgia: A 3-Arm Single-Blinded Randomized Clinical Trial
Michael Yelland; David Rabago, MD; Michael Ryan; Shu-Kay Ng; Dinusha Vithanachchi; Nagarajan Manickaraj; Leanne Bisset

January 2017

The HHPF hosted our 10th annual service learning project to Guadalajara, Mexico, in collaboration with HHPF member David de la Mora, MD, and the Palabra de Vida church volunteers. In addition to providing teaching for intermediate and advanced prolotherapists, HHPF board member Annette Zaharoff, MD, and HHPF instructors continued their work on our project to standardize prolotherapy injection techniques.

March 2017

The HHPF held our 49th service learning prolotherapy trip in Honduras. Twenty-one instructors and 32 learners at clinics in La Ceiba, Tela, and Olanchito treated over 1,500 patients during the two-week project. In addition, the HHPF vein treatment group treated 1,000 patients, and the ENT group performed 30 surgical procedures and did audiograms on over 200 patients during their weeklong service projects.

June 2017

David Rabago, MD, HHPF President, spoke on prolotherapy for knee osteoarthritis at the annual conference of The Orthobiologic Institute (TOBI), an international medical gathering focused on regenerative medicine teaching, tools and research, in Las Vegas, NV.

Annette Zaharoff, MD, HHPF Board of Directors, was a prolotherapy instructor at a weeklong conference and treatment clinic in Crete, Greece, along with Carl Osborn, DO,  Steven Cavallino, MD, and Susan Lanza, MD.